ITEM VIEW

Aetiology of pulmonary dysfunction in total hip replacement operations: The influence of nifedipine on the factors involved

dc.contributor.authorDu Toit, H. J.en_ZA
dc.contributor.authorMacfarlane, C. M.en_ZA
dc.contributor.authorTaljaard, J. J. F.en_ZA
dc.contributor.authorKing, J. B.en_ZA
dc.contributor.authorCooper, R. C.en_ZA
dc.date.accessioned2011-03-18T14:59:38Z
dc.date.available2011-03-18T14:59:38Z
dc.date.issued1987-05
dc.identifier.citationDu Toit, H.J. et al. 1987. Aetiology of pulmonary dysfunction in total hip replacement operations: The influence of nifedipine on the factors involved. S Afr Med J, 71(5):279-282.
dc.identifier.issn2078-5135 (online)
dc.identifier.issn0256-9574 (print)
dc.identifier.urihttp://hdl.handle.net/10019.1/7949
dc.descriptionCITATION: Du Toit, H.J. et al. 1987. Aetiology of pulmonary dysfunction in total hip replacement operations: The influence of nifedipine on the factors involved. S Afr Med J, 71(5):279-282.
dc.descriptionThe original publication is available at http://www.samj.org.za
dc.description.abstractENGLISH ABSTRACT: Patients undergoing total hip replacement surgery who developed pulmonary dysfunction (PD) demonstrated evidence of a complement activation and increased thromboxane A2 (TXA2) synthesis. In a double-blind study nifedipine (Adalat; Bayer-Miles) was shown to inhibit complement activation and TXA2 synthesis and thus appears to offer protection against PD.en_ZA
dc.format.extent4 pagesen_ZA
dc.language.isoen_ZAen_ZA
dc.publisherHealth & Medical Publishing Groupen_ZA
dc.subjectAetiologyen_ZA
dc.subjectDiseases -- Causes and theories of causationen_ZA
dc.subjectPulmonary diseasesen_ZA
dc.subjectHip replacementen_ZA
dc.titleAetiology of pulmonary dysfunction in total hip replacement operations: The influence of nifedipine on the factors involveden_ZA
dc.typeArticleen_ZA
dc.description.versionPublisher’s version
dc.rights.holderSouth African Medical Journalen_ZA


Files in this item

Thumbnail

This item appears in the following Collection(s)

ITEM VIEW